STOCKNO.DE
Institutional ownership intelligence
Research
Schedule 13G/A

ASLNEUR Schedule 13G/A filing by UBS

UBS reported beneficial ownership of 10 shares, representing 12% of ASLAN PHARMACEUTICALS LT-ADR in this filing.

FiledAug 8, 2024
Ownership dateJun 30, 2024
Reported shares10
Reported ownership12%
Ownership details

Voting and dispositive power reported in the filing

These figures describe the reporting filer’s disclosed voting and investment authority. They should be read together with the reported share count and percentage.

Sole voting power 6
Shared voting power 7
Sole dispositive power 8
Shared dispositive power 9
Source

Original filing and accession

Use the SEC filing as the primary source when you need the complete disclosure, footnotes, exhibits, or reporting-person details.

Reporting filer
UBS
CIK
CIK0001610520
Accession
0001610520-24-000138
Form
Schedule 13G/A
Open SEC filing View ASLNEUR ownership history
Read the filing in context

Understand what a Schedule 13 filing does—and does not—tell you.

How to read a Schedule 13G → Does a 13G mean the shares were just bought? → Filing date vs. ownership date →